NCT02676869View on ClinicalTrials.gov

Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

December 31, 2019

Conditions
Stage IV MelanomaStage III Melanoma
Interventions
DRUG

IMP321 (eftilagimod alpha)

"Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks"

DRUG

Pembrolizumab

Administered according to the approved label.

Trial Locations (7)

3181

Alfred Hospital, Melbourne

3353

Ballarat Hospital, Ballarat

4029

Royal Brisbane Womens Hospital, Brisbane

4102

Princess Alexandra Hospital, Brisbane

4120

Greenslopes Private Hospital, Brisbane

5042

Flinders Medical Centre, Adelaide

6150

Fiona Stanley Hospital, Perth

All Listed Sponsors
lead

Immutep Australia Pty. Ltd.

INDUSTRY

NCT02676869 - Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma | Biotech Hunter | Biotech Hunter